T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 58,912,075 shares of Viatris Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates reported holding 58,912,075 shares of Viatris Inc. common stock, representing 5.1% of the class.
- Sole voting power: The filing disclosed sole voting power over 56,678,388 shares.
- Sole dispositive power: T. Rowe Price reported sole dispositive power over all 58,912,075 shares.
- Shared power: Both shared voting power and shared dispositive power were reported as 0.
- Event date: The date of the event requiring the filing was stated as September 30, 2026.
- Filer classification: T. Rowe Price Associates is identified as an investment adviser, organized in Maryland, with a principal business address of 1307 Point Street, Baltimore, MD 21231.
T. Rowe Price's Amended Ownership Disclosure for Viatris Common Stock
T. Rowe Price Associates, Inc. submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Viatris Inc. (CUSIP 92556V106), whose principal executive offices are listed in the filing at 1000 Mylan Boulevard, Canonsburg, PA 15317. The filing was signed by Ellen York, Vice President of T. Rowe Price Associates, and dated November 16, 2026. The triggering event date for the amended disclosure is listed as September 30, 2026.
According to the filing, T. Rowe Price Associates beneficially owned 58,912,075 shares of Viatris common stock, equating to 5.1% of the class. Of that total, the firm reported sole voting power over 56,678,388 shares, while the remaining shares carried no reported voting power. Sole dispositive power was reported over the full 58,912,075 shares, with no shared dispositive power of any kind.
The filing includes a certification stating that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." T. Rowe Price Associates also declared that "the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
What Was Disclosed
T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 58,912,075 shares, or 5.1%, of Viatris Inc. common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 56,678,388 shares.




Please wait processing your request...